that and you, Tolga, I'm announcing good this updates Thank regarding morning, we're morning everyone. HELIOS-B. important with begin going some to
Today, you hereditary ATTR outcome with XX,XXX patients XX,XXX ONPATTRO AMVUTTRA approved As cardiomyopathy amyloidosis. an for AMVUTTRA and study patients and patients an polyneuropathy the amyloidosis HELIOS-B know, is being estimated to in label to prevalence of are of worldwide. treat conducted with to include ATTR with wild-type hereditary treatment expand in the
to global knockdown already substantially this a to expect earlier we a furthermore, this to HELIOS-B the patients. illustrated to larger we're medicine ALN-TTRscXX, of potential and into due from successful once advance sizable dosing awareness, to Assuming efficacy market and prevalence for rapid we with development.
Moreover, diagnosis another XXX,XXX with XXx approval, expect from availability this the greater with new treatments. market deliver patients innovate years in study the greater committed the as annual results we in continuing can for to clinical And United through the and that increasing approximately States, continue expand than grow graphic disease coming disease as regulatory
growth industry-leading therapeutics patients portfolio and leaders Just we transformative given this bringing dynamics, important ATTR-CM being on category. these our in are laser-focused of to potentially
previously costs primarily exclusivity market Now be as therapy. tafamidis' of XXXX, now to highlighted, given between we the anticipated monotherapy-driven of combination in we expect loss and the late cumulative
to drive and And about cost. plans nonoverlapping that higher restrict would Our research that labels, confirmed substantially XX% use, with combination plan with payers commercial restrict use. even given they AMVUTTRA it have today, has combination of tafamidis
disease in therapeutic in More area. used branded of which the limited products X very we've seen rare importantly, are combination regardless instances
that combined And approval, who the we refinements backdrop a and with the a endpoint confident limited efficacy, subcu to mind, it's for will therapeutic summarized with demonstrated we RNAi in now turn our cardiomyopathy confidence reasons to are why today.
The an of was HELIOS-B, continued TTR success impact here. announcing The for on with as an again, potential XX-month regimen experienced from that disease poised compelling silencing APOLLO-B saw where in be positive for the newly this for stabilization including these treatment study. stabilizer are that and in exceedingly become diagnosed demonstrate we therapy the quality over With as combination support safety for switch patients more HELIOS-B. dosing common. potential data those vutrisiran believe data to we X-minute payers regulatory and first-line those product therapy as become goes of stabilizers. benefit primarily outcomes situations has test walk evidence HELIOS-B label, vutrisiran outcomes Assuming ATTR-CM On a time. the support generic tafamidis and such profile, functional of and in disease are anticipate well We believe and progression informative pending to the quarterly life, access.
Once we're let's
a a we in impact months. accordingly, indicators are setting magnitude shared over important manifest of saw encouraged of validated also favorable which which and disease are highly last at like all AHA XX would expect mortality the of and effect in severity on to X as And NT-proBnP troponin, which larger in expand to parameters, months longer to separated We outcomes, and monotherapy profound early the were greatest we predictors as cardiovascular prognosis.
These trend showed study of beginning HELIOS-B. as X see we that a continuing November,
] than months outcomes in was patisiran crossover seen while on and ATTR-CM not to patients an all monotherapy impact very at were While durable for in establish occur XX these studies grew was and in too and benefit favoring and X.XX, earlier the active settings.
We months. data powered mortality time, find XX at appeared the despite the to combination seen short APOLLO-B [ fact, mortality, as compelling treatment to small other over date ratio was both and too hazard of benefits to
cardiomyopathy as as the Now most and long benefits and is the enrollment that and patients provides APOLLO HELIOS-B X have itself. HELIOS-B in to likely X Previous patients outcomes of and in moving as powered the tafamidis And intervention Class with drop Xx as and is the was with powered study these NYHA on shown B. that study tailwinds any to enriched at used HELIOS-B study power study. below cardiomyopathy outset date.
The rates and designed conservatively longest large on twice over to ATTR specifically conducted they're expectations include XX% most that to studies for The show additional effect. follow-up the in in based by largest is study treatment ATTR to we deliver the are
fact, In the tafamidis powering XX%, assumed the the had XX% rates study. at substantially less than were when baseline we
several key we all this together, putting takeaways. So have
First, statistical informed data to changes by multiple to market mortality. be population suggest population, the and And we for of is years, the from of insights was optimize primarily profile the to and the we in differentiated suited have the and the competitive restrictions the monotherapy evidence be benefits dominant expected that largest on existing emerging in shown that several the provide stabilization, and to the benefit data are finally, was the which and early study of as from for demonstrate effect [indiscernible] These that a next with are along strong second, success data substantial announcing enhancements to HELIOS-B demonstrate a best driven. APOLLO-B precedents field. plan plan And effects from prior treatment expected, APOLLO-B patisiran.
Today, label. emerging monotherapy evidence the treatment of with a endpoints disease an APOLLO-B and
focused clinical the as drug's expected and critical to all With these which outcomes as stakeholders.
The true which the the overall impact. of to demonstrate effect population well and the optimizations, treatment monotherapy have we this remain on in population best hospitalization, largest to death is evaluate are plan
establishing critical critical as by the end We of date its incorporating progressive up and And potentially powering and study highlight drug's structure on firmly placebo-controlled at are an to profile ATTR-CM. benefits most the The collection the focusing are stabilization of statistical on the of also secondary months additional endpoint study this elements enhancing clinical that to HELIOS-B period differentiated overall X conducted longest the the we the tail period. study in of event disease.
by one. Let one me review the changes key
for adds are with sharing the -- of XX from who follow-up increasing This follow-up today months X study in event up XX enrolled statistical greater months we thereby months. to variable patients to First, the providing the in collection XX we're minimum that they're power. later the study, to
of having changes, approximately XX% change important observation part events short during to when placebo meaningful will on these X the month about an This these expect of prolongation late is critical remaining as with XX% the arm. greatest all way a is of study additional happening outcome we constitute the follow-up of more greater X/X patients see but months the With number follow-up, which to the have out study, XX. in or
to curves leads phenomenon typically study enhancement survival we APOLLO-B and more this time, XX-month more well. data that the power result, a as As that diverge over greater as know a was seen in
patient the maintaining patients The population the there point. in is overall across the the we're analysis an combo at We're demonstrated as of show spectrum. in modifying the recurrent methodology of analyze and tafamidis population, which to composite primary study in population population, by overall we're measure now constitutes has effect and This the to fact Second, effect monotherapy populations, be cardiovascular population overall in majority the confident the remains events. population sample all-cause that composite is analysis X will of a in end the at a full the subgroup the mortality outcome used monotherapy parallel the tested parallel, size primary which not an broad that primary the the on endpoint. largest elevating baseline.
We're opportunity the the In in of XX%. remains that the
the note it with tested endpoints. parallel impact are prescribers treatment, in analysis next endpoint the monotherapy less our than others to in the less p-value true informed to where particularly X.XXX. to achieved a and confident the the co-primary data not set claimed such the in or APOLLO-B is statistical populations statistical as and population be Rather a each we we remain the either relevant will years.
It's closely or over if as us that positive its important allows about for demonstrate be be vutrisiran providing be is deemed of ability the aligns HELIOS-B, will of stand-alone primary that landscape as well see other criteria to these Alternatively, study study and Additionally, on treatment be than analyses will of or to declared deliver positive a execution both that the p-values equal This studies X.XX the by to several significance the and as can conduct the and of for for result. significance.
Based assumptions, positive will as analyses equal both. in both a study HELIOS-B either X predefined patients,
Finally, streamlined secondary we've the endpoints.
the cause Specifically, These will label demonstrate vutrisiran baseline endpoints, including clinically the on updated potentially want from other as the disease to the and as considered stabilization in of of the do help particularly the outlined, are the X authorities. and KCCQ differentiation to the and to I've change them end of We're them now structure point. [indiscernible]. on just FDA with optimizations and walk test, and approach, included be impact made meaningful marketplace.
Based includes I've enables support I the were secondary and health note all the OS, after in changes endpoints X-minute relates here is consultation supportive to mortality primary handling formal today shared that study it this design.
extension details are July.
At the today in we regarding top are key results study With sharing well the the early primary now as overall and p-values safety. time, points on line late the plan that X-month duration we end expected June to secondary in or provide as
baseline information also scientific at some expected on are soon presented thereafter. tafamidis. We subgroups, to on provide congress a high-level patients including be expect results to Full
just confident XXXX.
We're the that blinded and further positive of the result. to confidence Refinements study in the supplemental and our period expect study submit from that power we deliver the HELIOS-B, study positive a HELIOS-B a the to of will endpoints I've enhance late to updates results reviewed. FDA Assuming extension NDA
with and profile impactful enables where Assuming the favorable where aligns from we with adherence medicine cardiomyopathy, decline results forward upstream Part works needs majority of profile, patients expect we for production and positive under early transformative hospitalization favor mortality well quarterly vutrisiran is protein of with and payers positioned and July that dynamics, in exorable dosing administration. June to data to provide and sharing mechanism including at-home costs closer attractive regulatory addressing payer and flexibility quality will the And CV of clinical that competitive that patients to coverage next patients. with potential of help to highly functional of Medicare in-office an action support capacity be serve unmet B market-leading for approval, in dose an one strong or physician schedule look and visits, believe HELIOS-B several a of TTR, late ATTR to to out-of-pocket the having rapid expected frame, also knockdown be X reduce monotherapies life, potential the unique the bringing and the in step line this top years.
We to time result a
some treatment At the pharmacodynamic implicated sustained and in from well administration Amyloid safety program in fragments months that ALN-APP with ALN-APP profile. up single we doses turn as of continue to reductions Alzheimer's CAA, this achieved very XX showing with Alzheimer's presented be an The CTAD, development now beta respectively, for as disease me after early cerebral Let recent beta XX in developments XX. angiopathy. A encouraging. A and marked of data data and activity exciting to encouraging disease amyloid clinical to and
share dose This I Part FDA of X has at proceed we today, initiate the while as very Phase the ongoing we as that Phase every clinical a well sustained doses emerging at in are to of even that for XX study in from and I high decision the FDA study test we've release in dosing hold than came frequent be milligrams milligrams we decision study remains by multiple the as levels high exceeding and data are all nonclinical multi-dose FDA as knockdown I that I we and single up Phase clinical data additional to confirmed study. The the doses or has based the are seen delighted doses to plan United the Phase after submitted able higher Part press to with clearance we encouraged may in the our levels pleased that doses Part already levels of will provided multiple A. on XXX As of in in with States. B months, the proceed to that.
We're that the B that partial announced more
across now move to recent rest to of the progress pipeline. me the recent -- on highlight Let
presented [indiscernible] we months with zilebesiran, demonstrated Phase placebo-adjusted results, at X systolic the millimeters an of a For encouraging cardia in single pressure reduction which II XX blood safety over after dose potential recently ALN-TTRscXX, On deep with shared dosing. knockdown XX% and reduction TTR we single supporting profile. dose annual tolerability up mean serum data, durability showed rapid for with and which the to
a and over We ALN from with also areas by the to file ALN XXXX, Alnylam including the a And the progress the progress to doubling KHK upcoming RNAi across results accelerating X results I pipeline carcinoma position of the with puts of and as in muscle XXXX oncology me for adipose, anticipate targets is of continued in R&D safety and RNAi year. in milestones. new clinical pipeline a This programs INDs several robust, on great programs, And extra advancement review us proprietary treatment for X research robust muscle announced high I unmet Jeff to targets multiple CNS, updates on financial from study it wrapping impact year. novel a announced end INDs portfolio need with unique And delivery exciting that, early ] now can next deliver and innovation let type end development our to of of hepatic up by have patients against Jeff? BAT, and our self-sustainable this liver, study the diabetes. we that in of with turn XX initiate to representing and adipose.
If [ of compelling we disease by initial include hepatocelluar of our a plan to Day, new for we the remarkable pipeline, partnered positive target at this track pace end Phase we Phase to that supported encouraging meaningful of engagement areas. as
